CONCORDBIO - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.4
| Stock Code | CONCORDBIO | Market Cap | 11,533 Cr. | Current Price | 1,101 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 36.3 | Book Value | 174 ₹ | Dividend Yield | 0.97 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,218 ₹ | DMA 200 | 1,440 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 38.4 | MACD | -20.4 | Volume | 65,770 | Avg Vol 1Wk | 2,42,338 |
| Low price | 1,057 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.35 | Debt to equity | 0.00 |
| 52w Index | 4.05 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 27.2 |
📊 Concord Biotech (CONCORDBIO) shows decent fundamentals with strong ROCE (28.4%) and ROE (21.4%), but technical indicators (RSI 38.4, MACD negative, price below 50 & 200 DMA) suggest bearish momentum. This makes it a cautious candidate for swing trading rather than a strong one.
💡 Optimal Entry Price: Around ₹1,070–1,090, near recent support levels.
📈 Exit Strategy (if already holding): Consider exiting near ₹1,200–1,230 if momentum improves, or cut losses if price falls below ₹1,050 decisively.
Positive
- Strong ROCE (28.4%) and ROE (21.4%) indicate efficient use of capital.
- Debt-free balance sheet (Debt-to-equity 0.00).
- EPS of ₹30.1 shows solid earnings base.
- PEG ratio of 1.35 suggests reasonable valuation compared to growth.
Limitation
- Stock P/E (36.3) is higher than industry average (27.2), indicating premium valuation.
- Price trading below both 50 DMA (1,218) and 200 DMA (1,440), showing weak trend.
- Quarterly profit variation (-5.20%) indicates recent earnings pressure.
- Low trading volume compared to average, suggesting weak liquidity in short term.
Company Negative News
- Decline in FII holdings (-0.45%) shows reduced foreign investor confidence.
- Technical weakness with RSI near oversold zone and MACD negative.
Company Positive News
- PAT increased from ₹62.9 Cr. to ₹70.2 Cr. sequentially, showing resilience.
- DII holdings slightly increased (+0.03%), reflecting domestic support.
Industry
- Industry P/E at 27.2 is lower than the company’s, suggesting Concord trades at a premium.
- Biotech sector remains growth-oriented but volatile, with high sensitivity to R&D outcomes and regulatory approvals.
Conclusion
⚖️ Concord Biotech is fundamentally strong but technically weak at present. It may be suitable for cautious swing traders who enter near support (~₹1,070–1,090) and exit near resistance (~₹1,200–1,230). Risk management is crucial, as momentum indicators suggest limited upside in the short term.